A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia (NCT07096674)
A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial
🩺 Plain-English Summary (8th-Grade Level)
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Who can join: Review the eligibility criteria below.
Location: Auburn, alabama — Auburn, Alabama
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- Auburn, alabama — Auburn, Alabama
- Santa Ana, California — Santa Ana, California
- Miami, Florida — Miami, Florida
- Orlando, Florida — Orlando, Florida
- Winter Park, FL — Winter Park, Florida
- Stockbridge, GA — Atlanta, Georgia
- Atlanta, Georgia — Atlanta, Georgia
- Sterling Heights, Michigan — Sterling Heights, Michigan
- Hendersen, Navada — Henderson, Nevada
- Henderson, Nevada — Henderson, Nevada
- Denver, North Carolina — Denver, North Carolina
- Huntersville, North Carolina — Huntersville, North Carolina
- Cincinnati, Ohio — Cincinnati, Ohio
- Dublin — Dublin, Ohio
- Abington, Pennsylvania — Abington, Pennsylvania
- Willow Grove, Pennsylvania — Willow Grove, Pennsylvania
- North Charleston, South Carolina — North Charleston, South Carolina
- Austin, Texas — Austin, Texas
- El Paso, Texas — El Paso, Texas
- Toronto — Toronto, Ontario
- Bologna — Bologna, BO
- Verona — Verona, VR
- Móstoles, Madrid — Móstoles, Madrid
- Álava, Spain — Álava,
📞 Contact the Study Coordinator
Phone: (617) 468-5770
Email: ORX750-LTE@centessa.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Narcolepsy Type 1
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia — Cullman, Alabama
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 — Cullman, Alabama
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — Auburn, Alabama
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) — Miami, Florida
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence — Colorado Springs, Colorado
Explore by condition: All Narcolepsy Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.